If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
=== Surgery === While the total mesorectal excision (TME) operation has become the surgical gold standard for the management of rectal cancer, this is not so for colon cancer. Recently, the surgical principles underpinning TME in rectal cancer have been extrapolated to colonic surgery. Total or complete mesocolic excision (CME), use planar surgery and extensive mesenterectomy (high tie) to minimise breach of the mesentery and maximise lymph nodes yield. Application of this T/CME reduces local five-year recurrence rates in colon cancer from 6.5% to 3.6%, while cancer-related five-year survival rates in patients resected for cure increased from 82.1% to 89.1%.
Synephrine, under the developmental code name AB-102 and acting as a weak α1-adrenergic receptor agonist, is or was under development for the treatment of alopecia (hair loss) via topical administration. It has been found to cause contraction of arrector pili muscles (hair erector muscles), thereby increasing the force required to pluck hair and reducing hair shedding during brushing. It was originated by Applied Biology and is being developed by Safety Shot. As of February 2024, either no recent development has been reported or development has been discontinued. The drug has reached phase 1 clinical trials. Besides synephrine alone, a topical combination of phenylephrine, synephrine, and tyramine, with the code name DA-007, is also under formal development for the treatment of alopecia.
=== Refugee Lodges of Hispaniola === In 1748, on Cuba's neighboring island of Hispaniola, Freemasonry in Haiti was established by the Grande Loge de France with the St. Jean de Jérusalem Ecossais (English: St. John of Jerusalem) in Cap-Français, Saint-Domingue (known today as Haiti). The second Haitain Lodge was chartered in 1765 at Los Cayos, called Les Frères Réunis No. 1 (English: Reunited Brothers). When the Haitian Revolution started, a mass exodus of French and Saint-Domingue Creole refugee emigres left Saint-Domingue and settled in Cuba. Freemasonry was allowed to continue for some time during the war in Saint-Domingue, where Huet de la Chapelle had become the Grand Master of the French Provincial Grand Loge in 1795, until a change in government forced the Haitian Lodges to flee the island and relocate elsewhere. As that conflict then spilled over the border into Santo Domingo (known today as the Dominican Republic), the Eastern half of that island also experienced a wave of emigration as Spaniards fled the colony. Most of these refugees from Saint-Domingue and Santo Domingo landed in the port towns of Oriente Province, especially Baracoa and Santiago de Cuba. In 1798, La Bénéfique Concorde was reestablished in Baracoa, La Persévérance was reestablished in Santiago de Cuba, and La Concorde L'Amitié relocated to Havana. The charters for these French Lodges, however, specifically limited their activities to Hispaniola.
== Alternative PDRN sources == Variability in biological sources and production methods have shown to contribute to variations in biological activity of PDRN, more specifically with celullar pathways activation. As a results, alternative sources of PDRN are an ongoing research field that aims to better identify alternative sources with their associated effects. In addition to the standard animal-derived PDRN, there are other alternatives like plant, microbial and human-derived PDRN that have been studied to improve sustainbility and efficiency depending on the tissue model. These alternative sources gained more interest since low-molecular weight PDRN is related to better bioavailability, celullar uptake and skin penetration. Most alternative-source preparations contain DNA fragments with lower molecular weight than the animal-derived PDRN.
Sources: en.wikipedia.org
Beef hash Beef and rice Beef stew Chicken and rice Chicken stew Chili con carne Pork and scalloped potatoes Spaghetti with meat sauce Included in the box was a brown-foil accessory packet. The accessory packet contained:
Positive psychology is the branch of psychology dedicated to the study of well-being and related phenomena, like happiness and flourishing. It examines the factors and conditions of optimal human functioning. This inquiry focuses both on individual factors, like the experience of pleasure and pain and the role of character traits, and on societal factors, such as the way social institutions influence human well-being. At the emotional level, positive psychologists examine the different types of positive emotions, such as joy, amusement, and love. They seek to understand the conditions under which positive emotions arise, how they contribute to overall well-being, and how they differ from negative emotions. At the cognitive level, positive psychology studies how intelligence, wisdom, and creativity improve quality of life. It further explores the relation between cognitive and affective processes, for example, how cognitive interpretations evoke emotions and how emotions prompt thought processes. Another central subfield concerns the role of personality, in particular, how individuals differ regarding personality traits and how these traits impact well-being. The VIA model, an influential framework in positive psychology, analyzes personality based on six main virtues: wisdom, courage, humanity, justice, temperance, and transcendence. A closely related topic focuses on the role of the self, which encompasses the way a person conceptualizes and imagines themselves.
The work published by Banting, Best, Collip and Macleod represented the preparation of purified insulin extract suitable for use on human patients. Although Paulescu discovered the principles of the treatment, his saline extract could not be used on humans; he was not mentioned in the 1923 Nobel Prize. Ian Murray was particularly active in working to correct "the historical wrong" against Nicolae Paulescu. Murray was a professor of physiology at the Anderson College of Medicine in Glasgow, United Kingdom, the head of the department of Metabolic Diseases at a leading Glasgow hospital, vice-president of the British Association of Diabetes, and a founding member of the International Diabetes Federation. Murray wrote:
The common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating. Bupropion has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine. It is also associated with about 20% increased risk of headache. Bupropion raises blood pressure in some people. One study showed an average rise of 6 mm Hg in systolic blood pressure in 10% of patients. The prescribing information notes that hypertension, sometimes severe, is observed in some people taking bupropion, both with and without pre-existing hypertension. The safety of bupropion in people with cardiovascular conditions and its general cardiovascular safety profile remains unclear due to the lack of data. Bupropion has not been associated with QT prolongation at therapeutic doses but has been associated with QT prolongation in overdose. Seizure is a rare but serious adverse effect of bupropion. It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at 300 to 450 mg per day; the incidence climbs almost 10-fold for the higher-than-recommended dose of 600 mg. For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally 0 to 0.5% at the recommended doses. Rare cases of liver toxicity leading to death or liver transplantation have been reported for bupropion.
=== Hypoglycemia === Hypoglycemia, or abnormally low blood glucose, is an acute complication of several diabetes treatments. It is rare otherwise, either in diabetic or non-diabetic patients. The patient may become agitated, sweaty, weak, and have many symptoms of sympathetic activation of the autonomic nervous system resulting in feelings akin to dread and immobilized panic. Consciousness can be altered or even lost in extreme cases, leading to coma, seizures, or even brain damage and death. In patients with diabetes, this may be caused by several factors, such as too much or incorrectly timed insulin, too much or incorrectly timed exercise (exercise decreases insulin requirements) or not enough food (specifically glucose containing carbohydrates). The variety of interactions makes cause identification difficult in many instances. It is more accurate to note that iatrogenic hypoglycemia is typically the result of the interplay of absolute (or relative) insulin excess and compromised glucose counterregulation in type 1 and advanced type 2 diabetes. Decrements in insulin, increments in glucagon, and, absent the latter, increments in epinephrine are the primary glucose counterregulatory factors that normally prevent or (more or less rapidly) correct hypoglycemia. In insulin-deficient diabetes (exogenous) insulin levels do not decrease as glucose levels fall, and the combination of deficient glucagon and epinephrine responses causes defective glucose counterregulation. Furthermore, reduced sympathoadrenal responses can cause hypoglycemia unawareness.
Sources: en.wikipedia.org
=== Some documentary film awards === Grierson Awards Academy Award for Best Documentary Feature Joris Ivens Award, International Documentary Film Festival Amsterdam (IDFA), (named after Joris Ivens) Cinéma du Réel prizes, including the Grand Prix and Prix du premier film Loridan-Ivens / First Film Loridan-Ivens Award (formerly Joris Ivens Award), among others Filmmaker Award, Margaret Mead Film Festival Grand Prize, Visions du Réel
On July 22, 2024, the company announced via press release that A&W Food Services of Canada and the A&W Revenue Royalties Income Fund "have agreed to a strategic combination," which will lead to a new publicly traded QSR franchisor entitled A&W Food Services NewCo. The transaction was expected to close in October 2024, pending approval of the TSX and regulatory approval under the Competition Act (Canada).
== Therapeutics == Several mimetics of ELA have been developed for therapeutic purposes. Amgen has created a camel antibody and a small molecule agonist capable of mimicking the function of ELA towards it cognate receptor APLNR. The latter has entered phase 1 clinical trials for heart failure and acute kidney disease. Bristol Myers Squibb has also created its own small molecule agonist of APLNR. An opinion published in the Lancet in 2019 suggested that ELABELA could be used to treat intrauterine growth restriction and maternal morbidity linked to eclampsia.
=== Football clubs === In the 1960s, Inter Milan has its greatest period of success known as [La] Grande Inter ("Great Inter"), achieved when Helenio Herrera was their manager. He won seven trophies with the club. In 2004, Ferruccio Mazzola, Inter player during that period, accused him of distributing performance-enhancing drugs, including amphetamines, among the team players, especially the substitute players "who often served as guinea pigs for trying new pills and see if they worked." When he found out that some in the team were spitting them out, he dissolved them in coffee to make sure they were consumed, a practice known as Caffè di Herrera ("Herrera's Coffee"). In 2010, Inter sued Mazzola but lost the case, the court believed him. One of the reasons he spoke up were the serious medical conditions and/or deaths of some of his former members: Giuliano Taccola, then team's captain Armando Picchi (died aged 36 due to cancer), Marcello Giusti, Carlo Tagnin, Mauro Bicicli, Ferdinando Miniussi, Enea Masiero and Pino Longoni. He suspected the drugs to be the cause of their sufferings. in 2015, his brother Sandro, who denied everything at the beginning, admitted that the incidents happened. In the 1970s performance-enhancing drugs were used on a regular basis according to witnesses of that period, mostly in Ajax, Feyenoord and AZ Alkmaar during competitive matches, including the 1970 and 1972 Intercontinental Cups won by the first two cited clubs. Jan Peters recounted drug use before the big games. They seemed to work as he felt energy boosts and euphoria.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.